421 related articles for article (PubMed ID: 34865502)
41. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Ackermann CJ; Adderley H; Ortega-Franco A; Khan A; Reck M; Califano R
Drugs; 2020 Nov; 80(17):1783-1797. PubMed ID: 32986224
[TBL] [Abstract][Full Text] [Related]
42. First-line combination immunotherapy for metastatic non-small cell lung cancer.
Chen YM
J Chin Med Assoc; 2020 May; 83(5):433-441. PubMed ID: 32132380
[TBL] [Abstract][Full Text] [Related]
43. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
44. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
45. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
Bar J; Ofek E; Barshack I; Gottfried T; Zadok O; Kamer I; Urban D; Perelman M; Onn A
Lung Cancer; 2019 Dec; 138():109-115. PubMed ID: 31683093
[TBL] [Abstract][Full Text] [Related]
46. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
[TBL] [Abstract][Full Text] [Related]
47. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
48. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer.
Shen CI; Chao HS; Shiao TH; Chiang CL; Huang HC; Luo YH; Chiu CH; Chen YM
Sci Rep; 2021 Aug; 11(1):16122. PubMed ID: 34373555
[TBL] [Abstract][Full Text] [Related]
50. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Doroshow DB; Sanmamed MF; Hastings K; Politi K; Rimm DL; Chen L; Melero I; Schalper KA; Herbst RS
Clin Cancer Res; 2019 Aug; 25(15):4592-4602. PubMed ID: 30824587
[TBL] [Abstract][Full Text] [Related]
51.
Zhu G; Shi R; Li Y; Zhang Z; Xu S; Chen C; Cao P; Zhang H; Liu M; Pan Z; Liu H; Chen J
Front Immunol; 2021; 12():670040. PubMed ID: 34512623
[TBL] [Abstract][Full Text] [Related]
52. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy in Non-small Cell Lung Cancer: a Review.
Sequeira T; Almodovar MT
Port J Card Thorac Vasc Surg; 2023 Oct; 30(3):55-65. PubMed ID: 38499025
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older.
Saito Z; Fujita K; Okamura M; Ito T; Yamamoto Y; Kanai O; Hashimoto M; Nakatani K; Sawai S; Mio T
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1405. PubMed ID: 33934572
[TBL] [Abstract][Full Text] [Related]
57. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
58. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
Kumar S; Joga S; Biswas B; Dabkara D; Prasad KT; Singh N; Malik PS; Khurana S; Ganguly S; Muthu V; Batra U
Curr Probl Cancer; 2020 Jun; 44(3):100549. PubMed ID: 32035693
[TBL] [Abstract][Full Text] [Related]
59. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Ruiz-Patiño A; Arrieta O; Cardona AF; Martín C; Raez LE; Zatarain-Barrón ZL; Barrón F; Ricaurte L; Bravo-Garzón MA; Mas L; Corrales L; Rojas L; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Rizzo M; Ruiz R; Rolfo C; Archila P; Rodríguez J; Sotelo C; Vargas C; Carranza H; Otero J; Pino LE; Ortíz C; Laguado P; Rosell R;
Thorac Cancer; 2020 Feb; 11(2):353-361. PubMed ID: 31828967
[TBL] [Abstract][Full Text] [Related]
60. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
